STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks
Tag
STAT+
Live stream
RIVO news Listen to this section's headlines in an AI voice
Now:
Press play to start the stream
This browser does not support voice playback. Try Chrome, Edge or Safari.
STAT+: Online care is caught in the crossfire as states crack down on corporate medicine
Growing legislative scrutiny across multiple states targets the corporate structure underlying most direct-to-consumer telehealth businesses.
Pharmalot
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.
Health
STAT+: At the world’s largest cancer research meeting, data briefly took a backseat to grief
At the world's largest cancer research meeting, new data were plentiful. But this year, there was also a focus on grief.
Pharma
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
Biotech
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
Pharmalot
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
Pharmalot
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Health
STAT+: As Ebola outbreak in Central Africa grows, the U.S. turns itself into a fortress
The U.S. is taking extraordinary steps to keep Ebola out. But its policies may create risks for Americans infected overseas and discourage volunteers from responding to the outbreak.
Health tech
STAT+: Oura brings rings to the cuffless blood pressure party
In this edition of STAT Health Tech: A new wave of blood pressure monitoring wearables, Stanford asking patients about AI, and more.
Pharmalot
STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
In this morning's Pharmalittle roundup, we're reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more.
Health tech
STAT+: Blood pressure tech floods the market after FDA relaxes wearables oversight
Wearables with unvalidated blood pressure measuring tech are flooding the market after the FDA relaxed oversight of wellness devices.
Pharma
STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug
AI Prognosis
STAT+: Where patients and hospitals disagree about AI
In this edition of AI Prognosis, Brittany Trang takes a look at patients' role in how Stanford Health Care adopts AI tools, and more health AI news.
Health
STAT+: ‘Are we just going to give up and die like every other generation?’
Inside the longevity conference that brings together founders, investors, biohackers, and the generally death-averse to discuss how to forestall — or even beat — our demise.
Pharma
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial
Pharma
STAT+: Eli Lilly to buy three small vaccine developers
Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.
Biotech
STAT+: An AI biotech CEO sets the record straight on AI drug development hype
CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.
Pharma
STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
Biotech
STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.